New models of care 

The new models of care programme seeks to change how different providers organise their services to deliver better care for patients. We are working with our partners in the national Cancer Vanguard to make this commitment a reality.

  • Medicines optimisation

    Medicines optimisation is a key theme running throughout our new models of care programme. Recognising that the pharmaceutical industry would play a key role in any successful programme, we challenged organisations to submit proposals that would help us to deliver improvements in the use of cancer medicines.

    The challenge to industry – the Pharma Challenge – was issued with the support of the Association of British Pharmaceutical Industries (ABPI) and the Ethical Medicines Industry Group. Pharmaceutical companies were invited to submit proposals to improve the availability and delivery of cancer drugs which were judged by a panel of chief pharmacists, nurses, clinicians, health science and other professionals.

    One of these collaborations with the pharmaceutical company Amgen is led by UCLH Cancer Collaborative. The project is to map out and measure the most efficient out-of-hospital administration of denosumab (also known as Xgeva). Denosumab is a targeted therapy for the treatment of secondary breast cancer in the bone.

    Outputs from one-to-one stakeholder interviews, workshops and patient surveys have fed into a simulation modelling tool that allows different delivery scenarios, whether at hospital, in primary care, in the community or at home to be tested for financial and patient experience impact.

    This project has featured in a short film as part of the Royal Society of Medicine's 21st century programme. You can view the film below.

    The film features UCLH Cancer Collaborative director, Nick Kirby, and lead cancer pharmacist Pinkie Chambers, as well as Paola Domizio, a UCLH patient who is taking part in the pilot project.

    Related to this project is a pilot offering denosumab self-administration in the home. 12 patients have been enrolled onto the programme, with patient experience and associated learning captured. The results of this project, combined with the outcome of the simulation modelling, will help trusts within UCLH Cancer Collaborative understand how best to offer chemotherapy at home or in the community.

    For further information on Pharma Challenge visit the Cancer Vanguard website or contact

  • Early diagnosis industry challenge

    Led by UCLH Cancer Collaborative, the Cancer Vanguard launched a challenge to industry to improve the early diagnosis of cancer. The aim of the early diagnosis industry challenge is to engage expertise from outside the NHS to undertake a small number of high impact projects which will ultimately lead to a tangible improvement in the earlier diagnosis of cancer in the NHS. The call closed at the end of March 2017 and we will be updating this section as the project progresses. For more information contact

  • Commissioning innovations

    Changing the way that services are delivered requires devising new ways of commissioning paying for cancer services to enable innovative models of care to be introduced. UCLH Cancer Collaborative will be progressing this work in 2017/8. For more information contact

  • Radiotherapy partnerships

    A memorandum of understanding is being developed with the Royal Free London NHS Foundation Trust, North Middlesex University Hospital NHS Trust and UCLH for closer collaboration in radiotherapy. We will explore different options for integrated provision to improve patient ouctomes and ensure long term financial stability. For more information contact

  • Impact for diagnostics

    A business case is being developed to launch a new Cancer Alliance Diagnostic Hub in north east London. The hub will provide rapid access to a range of tests (MRI, endoscopy and ultrasound) and is a key part of meeting cancer waiting time standards as demand for diagnostics increases. For more information contact